Thailand and EFTA Sign Free Trade Agreement at Davos, Parliament Approves Ratification Submission

Thailand and the four European Free Trade Association states, Switzerland, Norway, Iceland, and Liechtenstein, signed a comprehensive free trade agreement on January 23, 2025, on the sidelines of the World Economic Forum's annual meeting in Davos. The signing, confirmed directly by EFTA's own official announcement, marks the formal conclusion of negotiations between Thailand and the EFTA bloc and is one of the most significant trade agreements Thailand has signed with a European trading partner. Nearly a year and a half later, on June 17, 2026, Thailand moved a concrete step closer to bringing that agreement into force: a joint session of Thailand's House of Representatives and Senate approved submitting the Thailand-EFTA FTA, alongside four other trade agreements, for formal ratification. Deputy Prime Minister and Minister of Commerce Suphajee Suthumpun announced the approval, which came during Parliament's third session, first annual ordinary session.

The agreement is signed and now cleared for the ratification process, but it is not yet ratified or in force. Signing a trade agreement, submitting it for ratification, and bringing it into full legal effect are three distinct steps under Thai and EFTA member-state procedure, and each of the five signatory governments still has its own domestic ratification process to complete before the agreement's tariff and regulatory provisions become legally claimable by traders on either side. The June 2026 parliamentary approval is a procedural green light to proceed with ratification, not ratification itself, and businesses on both sides should continue to treat the agreement's substantive terms as real and negotiated, closer to operative than at any point since signing, but still not yet claimable at the border.

What Parliament actually approved on June 17, 2026

That joint session also cleared four other trade instruments in the same sitting, a Thailand-Bhutan FTA, an ASEAN-China Free Trade Area upgrade, a protocol amending ATIGA, and the WTO fisheries-subsidies protocol, signaling that Thailand's parliament is working through a genuine backlog of pending trade agreements rather than fast-tracking EFTA specifically. DeeMED's companion update on this parliamentary session covers the vote itself, the officials involved, and what "approved for submission" actually means procedurally in more depth; this article focuses on the underlying agreement the vote concerns.

Why an EFTA agreement matters for Thailand specifically

EFTA is a distinct trading bloc from the European Union, comprising Switzerland, Norway, Iceland, and Liechtenstein, none of which are EU member states, though all four maintain close economic integration with the EU single market through separate arrangements. A free trade agreement with EFTA gives Thailand a negotiated tariff and market-access relationship with these four economies independent of, and running on a separate timeline from, Thailand's much larger and still-ongoing FTA negotiation with the European Union itself.

Switzerland in particular is a market of direct relevance to DeeMED's client base: it is home to a significant concentration of pharmaceutical, precision medical device, and specialty chemical manufacturing and demand, and a Thailand-EFTA agreement that reduces tariffs and aligns regulatory recognition between Thailand and Switzerland has direct relevance for Thai exporters of pharmaceutical ingredients, medical devices, and related regulated products seeking better commercial terms into the Swiss market, and for Swiss-origin regulated goods moving into Thailand.

What the agreement covers

A comprehensive FTA of this kind, negotiated between Thailand and a four-country bloc, typically covers tariff elimination or reduction schedules across a broad range of goods, rules of origin governing which products qualify for preferential treatment, provisions on trade in services, and, in many modern FTAs, commitments touching intellectual property, government procurement, and regulatory cooperation. EFTA's own announcement of the signing frames the agreement as comprehensive in scope, consistent with EFTA's pattern in its other bilateral and regional FTAs with Asian trading partners.

The specific tariff schedules, product-by-product reductions, and rules-of-origin thresholds contained in the signed text are not yet operative and are not something a Thai exporter or an EFTA-based importer can claim today. Signing fixes the negotiated text; it does not put that text into legal force. That step still requires each of the five parties, Thailand and each of the four EFTA states individually, to complete its own domestic ratification procedure.

What "signed but not ratified" means in practice

This distinction matters more than it might first appear, particularly for a trade agreement that generates real commercial excitement at the moment of signing. A signed but unratified FTA is not a source of enforceable preferential tariff treatment. A Thai exporter cannot yet claim a reduced or zero tariff rate into Switzerland, Norway, Iceland, or Liechtenstein under this agreement's terms, and an EFTA-based importer cannot yet claim preferential treatment on goods entering Thailand, because the agreement has not yet entered into force. Ratification, and in many cases accompanying domestic implementing legislation or regulation, has to happen first.

For a company planning around this agreement, whether importing Swiss-origin pharmaceutical equipment into Thailand or exporting Thai-origin goods toward the EFTA market, the practical guidance is to treat the agreement's terms as the framework that will eventually govern the relationship, useful for planning and negotiation purposes, and now meaningfully closer to that outcome given the June 2026 ratification-submission approval, while continuing to operate under Thailand's existing tariff schedules and existing trade arrangements with each EFTA state until ratification is actually completed and an entry-into-force date is set. Businesses that assume preferential treatment is already claimable based on the signing date, or based on this parliamentary approval to proceed, alone risk a customs dispute if they attempt to invoke terms that are not yet legally in force.

Positioning against Thailand's other pending FTA activity

The EFTA agreement sits alongside a broader pattern of active Thai trade diplomacy. Thailand is separately negotiating a full free trade agreement with the European Union itself, a larger and more complex negotiation still working through its own chapter-by-chapter process. The EFTA agreement, having already reached signature, is procedurally further along than the EU negotiation, but the two should not be confused. A Thailand-EFTA agreement covers Switzerland, Norway, Iceland, and Liechtenstein only; it has no bearing on Thailand's trade relationship with EU member states, which will depend on the outcome of the separate, still-ongoing EU negotiation.

This distinction is one Thai exporters and importers get wrong often enough that it is worth stating plainly: an agreement with EFTA does not extend to the EU by association, and an agreement with the EU, whenever it eventually concludes, will not automatically extend to EFTA. Switzerland's own economic relationship with the EU runs through a separate bilateral framework entirely outside both of these negotiations. A company assuming that progress on one negotiation implies parallel progress on the other, or that the two blocs will end up on the same tariff schedule, is working from a mistaken premise that could lead to miscalculated landed costs or missed preferential treatment on one side of the relationship while correctly claiming it on the other.

Why the regulatory recognition dimension matters as much as tariffs

Comprehensive FTAs increasingly do more than cut tariffs; they also build in mechanisms for regulatory cooperation and mutual recognition between the signatory parties, and this is often the dimension with the most direct relevance to a regulated-goods exporter rather than a commodity trader. For DeeMED's pharmaceutical, medical device, and specialty chemical clients, the eventual value of a Thailand-EFTA agreement is likely to run through both channels at once: reduced tariff exposure on goods moving in either direction, and any regulatory cooperation or standards-recognition commitments the final ratified text carries, which can materially shorten the compliance pathway for a Thai-origin product entering the Swiss, Norwegian, Icelandic, or Liechtenstein market, or for a Swiss-origin device or ingredient entering Thailand. Until ratification is confirmed and the agreement's implementing detail is published, neither the tariff schedule nor any regulatory recognition commitment can be treated as operative, but both are worth tracking together as the ratification process moves forward, since a Thai exporter evaluating the commercial case for entering the Swiss market will want to know both numbers, not just the tariff line.

What DeeMED clients should do now

Any company with Swiss, Norwegian, Icelandic, or Liechtenstein trade exposure involving Thailand should treat the January 23, 2025 signing and the June 17, 2026 ratification-submission approval together as confirmation that a negotiated agreement exists, has cleared a real domestic political step, and is moving toward eventual legal force, while continuing to plan under current tariff and regulatory arrangements until ratification is actually completed and an entry-into-force date is announced. Tracking the ratification status on both the Thai and EFTA sides is worth building into any medium-term market entry or supply chain planning involving these markets, since the agreement's tariff schedules and rules of origin will materially change landed cost and market access calculations once it enters into force.

DeeMED's Global Trade compliance services track the ratification status of Thailand's pending free trade agreements, including the EFTA agreement, and help exporters and importers plan for preferential tariff treatment as each agreement moves from signature toward actual legal force.